8sw7
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | '''Unreleased structure''' | ||
- | + | ==BG505 Boost2 SOSIP.664 in complex with NHP polyclonal antibody FP1== | |
+ | <StructureSection load='8sw7' size='340' side='right'caption='[[8sw7]], [[Resolution|resolution]] 3.37Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[8sw7]] is a 8 chain structure with sequence from [https://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1] and [https://en.wikipedia.org/wiki/Macaca_mulatta Macaca mulatta]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8SW7 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8SW7 FirstGlance]. <br> | ||
+ | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 3.37Å</td></tr> | ||
+ | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8sw7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8sw7 OCA], [https://pdbe.org/8sw7 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8sw7 RCSB], [https://www.ebi.ac.uk/pdbsum/8sw7 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8sw7 ProSAT]</span></td></tr> | ||
+ | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Immunodominance of antibodies targeting non-neutralizing epitopes and the high level of somatic hypermutation within germinal centers (GCs) required for most HIV broadly neutralizing antibodies (bnAbs) are major impediments to the development of an effective HIV vaccine. Rational protein vaccine design and non-conventional immunization strategies are potential avenues to overcome these hurdles. Here, we report using implantable osmotic pumps to continuously deliver a series of epitope-targeted immunogens to rhesus macaques over the course of six months to elicit immune responses against the conserved fusion peptide. Antibody specificities and GC responses were tracked longitudinally using electron microscopy polyclonal epitope mapping (EMPEM) and lymph node fine-needle aspirates, respectively. Application of cryoEMPEM delineated key residues for on-target and off-target responses that can drive the next round of structure-based vaccine design. | ||
- | + | Focusing antibody responses to the fusion peptide in rhesus macaques.,Cottrell CA, Pratap PP, Cirelli KM, Carnathan DG, Enemuo CA, Antanasijevic A, Ozorowski G, Sewall LM, Gao H, Greene KM, Allen JD, Ngo JT, Choe Y, Nogal B, Silva M, Bhiman J, Pauthner M, Irvine DJ, Montefiori D, Crispin M, Burton DR, Silvestri G, Crotty S, Ward AB bioRxiv. 2023 Jun 27:2023.06.26.545779. doi: 10.1101/2023.06.26.545779. Preprint. PMID:37425865<ref>PMID:37425865</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | [[Category: | + | </div> |
- | [[Category: | + | <div class="pdbe-citations 8sw7" style="background-color:#fffaf0;"></div> |
- | [[Category: Ozorowski | + | == References == |
- | [[Category: Pratap | + | <references/> |
- | [[Category: | + | __TOC__ |
+ | </StructureSection> | ||
+ | [[Category: Human immunodeficiency virus 1]] | ||
+ | [[Category: Large Structures]] | ||
+ | [[Category: Macaca mulatta]] | ||
+ | [[Category: Antansijevic A]] | ||
+ | [[Category: Ozorowski G]] | ||
+ | [[Category: Pratap PP]] | ||
+ | [[Category: Ward AB]] |
Revision as of 12:42, 26 July 2023
BG505 Boost2 SOSIP.664 in complex with NHP polyclonal antibody FP1
|